Acrylonitrile toxicity: Difference between revisions
(Acrylonitrile Toxicity) |
(Expand with concise EM-focused content: dual toxicity mechanism, clinical features, management) |
||
| (9 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
=Background= | ==Background== | ||
* | *Industrial chemical used in production of plastics, rubber, and acrylic fibers | ||
*'''Structure:''' Nitrile group linked to a vinyl group (CH2=CHCN) | |||
*Dual toxicity mechanism: direct irritant/hepatotoxin AND metabolized to form [[cyanide]] | |||
*Exposure routes: inhalation (most common occupational), dermal absorption, ingestion | |||
*Also released in combustion of synthetic materials (house fires) | |||
= | ==Clinical Features== | ||
* | *'''Early:''' Mucous membrane irritation, headache, nausea, vomiting, dizziness | ||
* | *'''Cyanide effects:''' [[Altered mental status]], [[seizures]], [[lactic acidosis]], [[hypotension]], [[cardiovascular collapse]] | ||
*'''Hepatotoxicity:''' Elevated transaminases, potential fulminant hepatic failure (delayed 1-3 days) | |||
*Dermal exposure: erythema, blistering, chemical burns | |||
= | ==Differential Diagnosis== | ||
*[[Cyanide | *[[Cyanide|Cyanide toxicity]] | ||
*[[ | *[[Hydrogen sulfide toxicity]] | ||
*[[Carbon monoxide toxicity]] | |||
*Other nitrile compound exposures | |||
=== | ==Evaluation== | ||
* | *Labs: CBC, BMP, hepatic panel, lactate, VBG/ABG | ||
*[[ | *Cyanide levels (often not available rapidly) | ||
*High anion gap [[metabolic acidosis]] with elevated lactate suggests cyanide component | |||
*Monitor serial hepatic panels for delayed hepatotoxicity | |||
==Management== | |||
*[[Cyanide#Treatment|Cyanide antidotes]]: hydroxocobalamin (preferred) or sodium thiosulfate | |||
*[[N-Acetylcysteine]] (NAC) for hepatoprotection | |||
*Aggressive decontamination: remove clothing, copious water irrigation for dermal exposure | |||
*Supportive care: IV fluids, vasopressors for hypotension, benzodiazepines for seizures | |||
==Disposition== | |||
*Admit all symptomatic patients for monitoring (hepatotoxicity may be delayed) | |||
*Asymptomatic exposures: observe minimum 4-6 hours with serial labs | |||
==See Also== | |||
*[[Cyanide]] | |||
*[[Smoke inhalation]] | |||
==References== | |||
<references/> | |||
[[Category:Toxicology]] | |||
Latest revision as of 01:17, 21 March 2026
Background
- Industrial chemical used in production of plastics, rubber, and acrylic fibers
- Structure: Nitrile group linked to a vinyl group (CH2=CHCN)
- Dual toxicity mechanism: direct irritant/hepatotoxin AND metabolized to form cyanide
- Exposure routes: inhalation (most common occupational), dermal absorption, ingestion
- Also released in combustion of synthetic materials (house fires)
Clinical Features
- Early: Mucous membrane irritation, headache, nausea, vomiting, dizziness
- Cyanide effects: Altered mental status, seizures, lactic acidosis, hypotension, cardiovascular collapse
- Hepatotoxicity: Elevated transaminases, potential fulminant hepatic failure (delayed 1-3 days)
- Dermal exposure: erythema, blistering, chemical burns
Differential Diagnosis
- Cyanide toxicity
- Hydrogen sulfide toxicity
- Carbon monoxide toxicity
- Other nitrile compound exposures
Evaluation
- Labs: CBC, BMP, hepatic panel, lactate, VBG/ABG
- Cyanide levels (often not available rapidly)
- High anion gap metabolic acidosis with elevated lactate suggests cyanide component
- Monitor serial hepatic panels for delayed hepatotoxicity
Management
- Cyanide antidotes: hydroxocobalamin (preferred) or sodium thiosulfate
- N-Acetylcysteine (NAC) for hepatoprotection
- Aggressive decontamination: remove clothing, copious water irrigation for dermal exposure
- Supportive care: IV fluids, vasopressors for hypotension, benzodiazepines for seizures
Disposition
- Admit all symptomatic patients for monitoring (hepatotoxicity may be delayed)
- Asymptomatic exposures: observe minimum 4-6 hours with serial labs
